Manulife

FACT SHEET

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

SEP 2026

Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

Risk Classification

Risk classification is based on type of fund.

Low — Mid — High

Money Market — Fixed Income — Balanced — Equity

Fund Information

Inception Date	:	18 Oct 21
Inception Price	:	USD 1.0000
Fund Size	:	USD 522,677.25
Number of unit	:	427,168.83
Net Asset Value/Unit [3]	:	USD 1.2236
Fund Currency	:	USD
Type of fund	:	Equity
Valuation	:	Daily
Custodian Bank	:	Bank DBS Indonesia
Annual Management Fee	:	2.50%
Bloomberg Code	:	MATKGMU IJ
Fund Manager	:	PT Manulife Aset Manajemen Indonesia

Allocation

Equity	:	80 - 100 %
Money Market	:	0 - 20 %


Portfolio

Equity	:	99.14%
Money Market	:	0.86%


Note

1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
2) The benchmark is MSCI World Healthcare Net Total Return USD Index.
3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception



Monthly Performance Last 3 Years



Fund Performance

Performance in USD per (30/09/26)


	1 mo	3 mo	6 mo	YTD	1 yr	3 yr [1]	5 yr [1]	Since Inception [1]
MANTKG	0.00%	3.59%	10.57%	4.46%	15.91%	7.76%	n/a	4.16%
BM [2]	-1.79%	3.33%	10.30%	4.77%	16.38%	8.95%	n/a	5.33%

Yearly Performance

	2025	2024	2023	2022	2021	2020	2019	2018
MANTKG	12.68%	2.19%	1.17%	-4.60%	n/a	n/a	n/a	n/a
BM [2]	15.55%	0.94%	3.76%	-5.68%	n/a	n/a	n/a	n/a

Top Holdings* & Sector Allocation

Mutual Fund - BlackRock Global Funds - World Healthscience Fund



Non Affiliates

Investment Manager Commentary

Global healthcare equities delivered a mixed performance in September, as the sector's defensive characteristics were balanced by a challenging macroeconomic backdrop. Escalating geopolitical tensions in the Middle East disrupted energy supply and pushed Brent crude back above USD100 per barrel, renewing concerns that higher energy costs could prolong global inflationary pressures. Against this backdrop, major central banks continued to tighten monetary policy. The Fed raised its policy rate by 25bps, in line with expectations, while maintaining a hawkish stance and signaling the potential for further rate hikes. The 10-year US Treasury yield rose to 5.28%, its highest level since 2007, amid concerns over inflation, higher interest rates, and elevated US debt levels. Higher global bond yields created equity valuation headwinds, particularly for growth-oriented healthcare companies, while performance varied considerably across subsectors. Biotechnology and medical technology showed relative strength in selected areas, while parts of the pharmaceutical sector faced greater pressure. This divergence highlighted an increasingly selective market environment, with investors focusing on company fundamentals and growth prospects. Looking ahead, the sector continues to benefit from long-term structural drivers, including healthcare innovation, ageing populations and rising chronic disease prevalence. Nevertheless, elevated interest rates and company-specific developments could keep near-term volatility high.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 30 sales offices, Manulife Indonesia serves around 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit www.manulife.co.id.